Paul Martini Prize 2014
Paul Martini Prize 2013
Paul Martini Prize 2012
Paul Martini Prize 2011
Paul Martini Prize 2010
Paul Martini Prize 2009
Paul Martini Prize 2008
Paul Martini Prize 2007
Paul Martini Prize 2006
Paul Martini Prize 2005
Paul Martini Prize 2004
Paul Martini Prize 2003
Paul Martini Prize 2002
Paul Martini Prize 2001
Prize Winners
since 1969
Jury
Announcement
Winner of the Paul Martini Prize since 1969 print page
2014 Prof. Dr. med. Matthias Tschöp (Munich/Germany)
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys and humans. (Science Translational Medicine 2013)

Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia. (Gut 2013)

GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats. (Diabetes 2013)

Targeted estrogen delivery reverses the metabolic syndrome. (Nature Medicine 2012)
2013 Prof. Dr. med. Andreas Engert (Cologne/Germany)
Reduced treatment intensity in patients with early stage Hodgkin's lymphoma. (New England Journal of Medicine 2010)

Reduced intensity of chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. (The Lancet 2012)

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. (Journal of Clinical Oncology 2010)

Brentuximab vedotin for relapsed or refractory CD30-positive hematologic malignancies – the GHSG experience. (Blood 2012)
2012 PD Dr. med. Jan Wehkamp (Stuttgart/Germany)
Reduction of disulphide bonds unmasks potent antimicrobial activity of human ß-defensin 1 (Nature 2011)

Prof. Dr. med. Stephan Stilgenbauer (Ulm/Germany)
Prof. Dr. med. Michael Hallek (Köln/Germany)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (The Lancet 2010)
2011 PD Dr. med. Kaan Boztug (Wien/Austria)
Prof. Dr. med. Christoph Klein (München/Germany)
Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome (New England Journal of Medicine 2010;363:1918-27)
2010 Prof. Dr. med. Veit Hornung
Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization (Nature Immunology 2008)
AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC (Nature 2009) RIG-I-dependent sensing of Poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate (Nature Immunology 2009)
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin-1ß production (Nature Immunology 2010)

PD Dr. med. Jürgen Ruland

Adjuvanticity of a synthetic cord factoranalogue for subunit Mycobacterium tuberculosis vaccination requires FcRy-Syk–Card9–dependent innate immune activation (Journal of Experimental Medicine 2009)
Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells (Journal of Experimental Medicine 2009)
Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence (Nature 2009) Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin- 1ß production (Nature Immunology 2010)
2009 Prof. Dr. med. Ralf Bargou (Würzburg/Germany)
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

Prof. Dr. med. Frank M. Brunkhorst (Jena/Germany)
Dr. med. Christoph Engel (Leipzig/Germany)

1. Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis
2. Epidemiology of Sepsis in Germany: Results from a National Prospective Multicenter Study
2008 Prof. Dr. med. Christian Weber
Prof. Dr. rer.nat. Jürgen Bernhagen
(Aachen/Germany)
MIF is a noncognate ligand for CXC chemokine receptors in inflammatory and atherogenic cell recruitment
2007 Prof. Dr. Roland Schüle (Freiburg/Germany)
1. LSD1 demethylates repressive histone marks to promote androgen receptor dependent transcription
2. Co-operative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression
3. Androgen receptor coactivators LSD1 and FHL2 predict risk of prostate cancer recurrence

Prof. Dr. med. Christian Strassburg (Hannover/Germany)

1. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene
2. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferae haplotype

2006 Prof. Dr. med. Bodo Levkau (Essen/Germany)
1. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
2. HDL stimulates myocardial perfusion in vivo
3. The immunosuppressant FTY720 induces eNOS-dependent arterial vasodilation via the lysophospholipid receptor S1P3
4. High-density lipoproteins and their constituent sphingosine-1-phosphate directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 sphingolipid receptor
2005 PD Dr. med. Johannes Oldenburg (Frankfurt/Germany)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
2004 H. Ardeschir Ghofrani (Gießen, Germany)
1. Oral Sildenafil as Long-Term Adjunct Therapy to Inhaled Iloprost in Severe Pulmonary Arterial Hypertension
2. Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension
3. Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension
4. Sildenafil for treatment of lung fibrosis und pulmonary hypertension: a randomised controlled trial
2003 Helmut Goldschmidt (Frankfurt, Germany)
1. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma
2. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy
3.Polymorphisms of the tumor necrosis factor-alpha gene promotor predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma
4. Dose-dependent effect of thalodomide on overall survival in relapsed multiple myeloma
2002 Ulrich Laufs (Bad Homburg, Germany), Christopher Heeschen (Frankfurt, Germany), Matthias Endres (Berlin, Germany)
1. Neuroprotection Mediated by Changes in The Endothelial Actin Cytoskeleton
2. Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndroms
3. Supression of Endothelial Nitric Oxide Production After Withdrawal of Statin Treatment Is Mediated by Negative Feedback Regulation of Rho GTPase Gene Transcription
4. Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice

Wolf-Karsten Hofmann (Frankfurt, Germany)

1. Resistance of PH+ acute lymphoblastic leukemia to the tyrosine kinase inhibitor STI571 (Glivec ™) is associated with distinct gene expression profiles implicating diverse mechanisms of resistance
2. Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 (Glivec ™) has a unique BCR-ABL gene mutation
2001 Martin Fromm (Stuttgart, Germany)
1. Inhibition of P-glycoprotein mediated drug transport: A Unifying mechanism to explain the interaction between digoxin and quinidine
2. Bedeutung des intestinalen Stoffwechsels und des ABC-Transporterproteins G-Glykoprotein für die Pharmakokinetik und Wirkung von Arzneimitteln
2000 Robert Bals (München, Germany)
Untersuchungen zur Biologie antimikrobieller Peptide und deren Verwendbarkeit als Pharmaka

Gunther Hartmann (München, Germany)

Delineation of a CpG Phosporothioate Oligodesooxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo
1999 Stefanie M. Bode-Böger (Hannover, Germany), Rainer H. Böger (Hannover, Germany)
1. L-Arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia
2. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease
3. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease

Andreas Greinacher (Greifswald, Germany)

Klinik, Diagnostik, Pathophysiologie und Therapie der Heparin-induzierten Thrombozytopenie
1998 Thomas Ruzicka (Düsseldorf, Germany), Günter Michel (Düsseldorf, Germany), Bernhard Homey (Düsseldorf, Germany), Lajos Kemény (Szeged, Hungary)
1. A Short-Term Trial of Tacrolimus Ointment For Atopic Dermatitis
2. Antioncogene P53 and Mitogenic Cytokine Interleukin-8 Aberrantly Expressed in Psoriatic Skin Are Inversely Regulated by the Antipsoriatic Drug Tacrolimus (FK506)
3. FK506 in the treatment of inflammatory skin disease: promises and perspectives
4. Topical FK506 Suppresses Cytokine and Co-stimulatory Molecule expression in Epidermal and Local Draining Lymph node Cells during Primary Skin Immune Responses
1997 Hans-Uwe Simon (Zürich, Switzerland)
Novel therapeutic strategies via the apoptosis pathways to resolve chronic eosinophilic inflammation
1996 Thomas Gramatté (Dresden, Germany)
Die Lokalisationsabhängigkeit der Arzneistoffresorption im Dünndarm des Menschen
1995 Sabine Kurz (Freiburg, Germany), Thomas Münzel (Freiburg, Germany)
New Insight into Mechanisms Underlying the Phenomenon of Nitrate Tolerance

Stefan Rosewicz (Berlin, Germany)

Retinoids: Novel, Experimental Strategy for the Treatment of Human Pancreatic Adenocarcinoma
1994 Claus Kroegel (Freiburg, Germany), Christian Virchow (Freiburg, Germany), Christoph Walker (Freiburg, Germany)
Untersuchung zur Bedeutung von Th2-Lymphozyten und ihre Rolle bei der Aktivierung von eosynophilen Granulozyten am Modell der endobronchialen Allergenprovokation von Asthmatikern
1993 Peter J. Meier-Abt (Zürich, Switzerland)
Bile Excretory Pathways
1992 Marion Brach (Berlin, Germany), Friedhelm Herrmann (Freiburg, Germany)
Ara-C: Synergismus mit Zytokinen und molekulare Wirkungsmechanismen

Thomas Münzel

Endopeptidase-Inhibition

K. Heyo Kroemer (Stuttgart, Germany)

Untersuchung zur Vorhersage der Variabilität des Arzneimittelnetabolismus in vivo aus in vitro Experimenten und der Konsequenzen für die Arzneimittelwirkung am Beispiel von Propafenon und Verapamil
1991 Dieter Voegele (Frankfurt, Germany), Dierk Brockmeier (Frankfurt, Germany)
In vivo - in vitro Korrelation der Arzneistofffreisetzung
1990 Gunnar Alván (Huddinge, Sweden)
1. Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis
2. Diuretic effect and diuretic efficiency after intravenous dosage of furosemide
3. Reversible hearing impairment related to quinine blood concentration in guinea pigs

H.-J. Gabius (Marburg, Germany), S. Gabius (Göttingen, Germany), Tibor Hajto (Arlesheim, Switzerland), K. Hostanska (Göttingen, Germany), Andrea Trittin (Göttingen, Germany)

Klinischer Nachweis von Immunodulation durch Lektine im Rahmen der Misteltherapie
1989 Stefan C. Meuer (Heidelberg, Germany)
Low-dose Interleukin-2 induces systemic responses against HbsAG in immunodeficient non-responders to hepatitis B vaccination
1988 Peter M. Lauven (Bonn, Germany), J. Schüttler (Erlangen, Germany), Helmut Schwilden (Bonn, Germany)
Hypnotic Treshold Concentrations of Methohexitone and Closed-Loop Feedback Control of Methohexital Anaesthesia by Quantitative EEG Analysis in Humans

Kevin J. Scanlon (Duarte (CA) USA)

Biochemical basis for cisplatin an 5-flourouracil synergism in human ovarian carcinoma cells
1987 kein PM-Preis
1986 Jochen Thormann (Bad Nauheim, Germany)
Dynamic Analysis of Endsystolic Pressure/ Volume Relationships during Therapeutic Interventions

Joachim Chrubasik (Heidelberg, Germany)

Zur spinalen Infusion von Opiaten und Somatostasin
1985 Lutz-Henning Block (Basel, Switzerland)
(-)-Adrenaline-induced, calcium-dependent phosphorylation in human platelets: increase in essential hypertension, inhibition by Verapamil

Gustav Georg Belz (Wiesbaden, Germany), Dieter Palm (Frankfurt, Germany), Anton Wellstein (Frankfurt, Germany)

Kinetik-Dynamik
1984 Otto-Erich Brodde (Essen, Germany)
Quantitative Bestimmung adrenerger alpha- und beta-Rezeptoren des Menschen: Eine Methode zur genauen Beurteilung klinisch-pharmakologischer und therapeutischer Maßnahmen

H. G. Dammann (Hamburg, Germany), Peter Müller (Heidelberg, Germany), B. Simon (Heidelberg, Deutschland)

Humanpharmakologische Untersuchung zur Wirksamkeit von Ulkustherapeutika
1983 Adrian Küpfer (Bern, Switzerland), H. Seyberth (Marburg, Germany)
Pharmacogenetics of mephenytoin: A new drug hydroxilation polymorphism in man 'Ductus Arteriosus'
1982 W. Doering (München, Germany), Jürgen Scherberich (Frankfurt/ M., Germany), Gustav Georg Belz (Wiesbaden, Germany)
Chinidin-Digoxin: Pharmakokinetik und Pharmakodynamik einer exemplarischen Arzneimittelinteraktion
1981 Kein PM-Preis
1980 Winfried Gunselmann (Wuppertal, Germany)
Multivariate Prognosemodelle in der Medizin

Jeffrey Aronson, Alan Ford, David Grahame-Smith (Oxford, UK)

Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' tissues during glycoside therapy.
1979 D. Loew (Wuppertal, Germany), Klaus Breddin (Frankfurt/M., Germany), Klaus Lechner (Wien, Austria), Karl Überla (München, Deutschland), E. Walter (Heidelberg, Germany)
Secondary Prevention of Myocardial Infarction, a Comparison of Acetylsalicylic Acid, Placebo and Phenprocoumon

Hans-Jörg Ruoff (Wuppertal, Germany)

Adenylate Cyclase in Human Gastric Mucosa
1978 kein PM-Preis
1977 Melvyn F. Greaves (London, UK)
Immunological Detection and Monitoring of Leukaemic Cells
1976 Michel Eichelbaum (Stuttgart, Germany)
Ein neuentdeckter Defekt im Arzneimittelstoffwechsel des Menschen: Die fehlende N-Oxydation des Spartein

Bodo-Eckehard Strauer (Düsseldorf, Germany)

Dynamik, Koronardurchblutung und Sauerstoffverbrauch des normalen und kranken Herzens
1975 Lucius Dettli (Basel, Switzerland)
Elimination Kinetics and Dosage Adjustment of Chemotherapeutic Agents in Patients with Kidney Diseases

Alan Richens (London, UK)

A Study of the Pharmacokinetics of Phenytoin (Diphenylhydantoin) in Epileptic Patients and the Development of a Practical Scheme for Making Dose Increments
1974 Alasdair Muir Breckenridge (London, UK), Michael L'Estrange Orme (London, UK)
Pharmacokinetics, Pharmacodynamics and Interaction of Warfarin
1973 John Raymond Hobbs (London, UK), Hussein Salih (London, UK), Herschel Flax (London, UK)
Evaluation of Hormone Dependence of Breast Cancer for the Individual Patient
1972 Herbert Remmer (Tübingen, Germany), Hans Felch (Friedrichshafen, Germany), Freiherr von Olderhausen, Reinhard Fleischmann (Tübingen, Germany)
Determination of Drug Metabolizing Enzymes in Needle Biopsies of Human Liver

Emil H. Graul (Marburg, Germany), Adolf Habermehl (Marburg, Germany)

Tracerkinetik

Heinz Held (Tübingen, Germany)

Über die Veränderung des Abbaus von Arzneimitteln unter verschiedenen Bedingungen. Klinische und tierexperimentelle Untersuchungen
1971 Erich E. Gabbe (Hamburg, Germany), Hellmut C. Heinrich (Hamburg, Germany)
Experimental Basis of the Diagnosis and Oral Therapy of Prelatent, Latent and Manifest Iron Deficiency

David J. Finney (Edinburgh, UK)

Statistical Logic in the Monitoring of Reactions to Therapeutic Drugs
1970 Werner Kübler (Gießen, Germany)
Pharmakokinetische Methoden zur Ermittlung der enteralen Resorption
1969 Jules Angst (Zurich, Switzerland), Poul Christian Baastrup (Glostrup, Denmark), Poul Grof (Hamilton, Canada), Mogens Schou (Risskov, Denmark), Peter Weis (Basel, Switzerland)
Methodogical Problems of Prophylactic Trials in Recurrent Affective Disorders

Wilhelm Börner (Würzburg, Germany), Stefan Grehn (Würzburg, Germany), Erich Moll (Würzburg, Germany), Erich Rau (Würzburg, Germany)

Messung der Asorption des Fingerknochens mit einem 125 J-Scanner

K. H. Rahn (Münster, Germany), Peter G. Dayton (Atlanta, USA)

Studies of the Metabolism of Guanethidine in Hypersensitive Patients
Paul Martini | Foundation | Events | Paul Martini Prize | Publications | Contact | Imprint